Glial fibrillary acidic protein (GFAP) is considered to be a highly specific marker for glia. Here, we report on the expression of GFAP in neurons in the human hippocampus. Intriguingly, this neuronal GFAP is coded by out-of-frame splice variants and its expression is associated with Alzheimer pathology. We identified three novel GFAP splice forms: D 135 nt, D exon 6 and D 164 nt. Neuronal GFAP is mainly observed in the pyramidal neurons of the hippocampus of Alzheimer and Down syndrome patients and aged controls, but not in neurons of patients suffering from hippocampal sclerosis. Apparently, the hippocampal neurons in patients with Alzheimer's disease pathology are capable of expressing glia-specific genes.
Alzheimer's disease (AD) is the main cause of senile dementia 1 and is accompanied by neuronal cytoskeletal pathology, amyloid plaques and gliosis. Characteristic deposits of aberrant proteins, such as b-amyloid (A 40/42 ), 2 hyperphosphorylated tau 3 and þ 1 proteins 4 are observed in the neuropathological hallmarks of AD, that is, the plaques, tangles and neuropil threads. Furthermore, it is evident that the severity of the AD pathology strongly correlates with the density of the activated astrocytes. 5 In these cells, the expression of glial fibrillary acidic protein (GFAP) is strongly upregulated. 6, 7 The þ 1 proteins that accumulate in brains of AD patients are proteins with a wild-type N-terminus and an out-of-frame C-terminus. 8 Owing to molecular misreading, small deletions occur in mRNA in or adjacent to short repetitive sequences, resulting in frameshifted mRNA and consequently the translation of þ 1 proteins. 8, 9 In a previous study, we have shown that molecular misreading of two human genes occurs, that is, amyloid precursor protein (APP) and ubiquitin B (UBB). Both aberrant proteins, APP þ 1 and UBB þ 1 , are present in aggregates and coexpressed in neurons in the hippocampus and cortex of AD patients, Down syndrome (DS) patients and aged nondemented controls. 4 The mechanism of molecular misreading is still elusive; however, we envision that the deletions are either introduced during transcription or might reflect post-transcriptional modifications. 10 Apparently, high expression of a gene facilitates the detection of molecular misreading, as we have shown earlier for vasopressin in the homozygous Brattleboro rat 11 and APP in DS patients. 4 Therefore, the high level of GFAP expression in AD and DS patients prompted us to study whether faulty GFAP mRNAs are expressed in these patients. The human GFAP gene is located on chromosome 17 12 and encodes a class III intermediate filament protein, which is expressed in astrocytes. 13 Recently, it has been shown that mutations in the GFAP gene are associated with Alexander disease, 14, 15 which is a progressive degenerative neurological disorder. The disease is characterized by cytoplasmic inclusions in astrocytes containing GFAP, the so-called Rosenthal fibers. 16 Alexander disease is the first example of neuropathology caused by mutations in the GFAP gene.
In this study, we focused on the human enthorinal cortex and hippocampus, since this area is the earliest and most affected area in AD. 17, 18 During the course of our experiments, we observed that frameshifted GFAP is indeed expressed in the hippocampus of AD and DS patients. It turned out that this aberrant GFAP protein was not the result of classical molecular misreading, but the result of alternative splicing of GFAP pre-mRNA. To our surprise, we observed that this GFAP protein is expressed in hippocampal neurons in AD and DS patients.
Materials and methods

Human brain material
Post-mortem human brain material was obtained from the Netherlands Brain Bank in Amsterdam, the Netherlands (coordinator: Dr R Ravid). The hippocampi were obtained at autopsy and fixed for 1 month by immersion in 4% formalin in neutral phosphatebuffered saline (PBS, pH 7.4). All cases were neuropathologically confirmed using convential histopathological stainings including Bodian, methenamine-silver and Congo red. In addition, hippocampal tissue was obtained by tissue biopsy from pharmacoresistant temporal lobe epilepsy patients (Dr CWM van Veelen and Dr PC van Rijen UMCU, Utrecht The Netherlands) and was fixed in 4% buffered formalin for 1 day.
Immunocytochemistry
Paraffin sections (6 mm thick) or 50 mm thick vibratome sections of post-mortem hippocampi of 15 AD patients, five DS patients, 25 nondemented controls and epileptic tissue biopsy material of 12 pharmacoresistant temporal lobe epilepsy patients were stained for the presence of GFAP wt and GFAP þ 1 . The paraffin sections were deparaffinized in xylene and graded ethanol dilution series and washed in Tris-buffered saline (TBS; pH 7.6). These sections and the vibratome sections were incubated with 100% formic acid on a rocking table for 30 min, rinsed in distilled water for 30 min and in PBS (pH 7.6) for 30 min. The vibratome sections were treated with graded methanols and finally with 20% methanol/ 0.3% H 2 O 2 to inhibit pseudoperoxidase activity of erythrocytes. Subsequently, the sections were incubated with various polyclonal antibodies as described previously. 4 These antibodies included: GFAP wt (i) DAKO raised against bovine GFAP (1 : 300 paraffin, 1 : 2000 vibratome; DAKO, Carpinteria, CA, USA), (ii) Sigma raised against human GFAP (1 : 1000) or (iii) Dahl 19 (1 : 2000), GFAP þ 1 (epitope DRGDAGWRGH, 1 : 1000, bleeding 010498), APP þ 1 (1 : 250, bleeding 020294), UBB þ 1 (1 : 400, Ubi2 bleeding 010994) and GFAP þ 1 preimmune serum (1 : 1000, bleeding 270198).
Confocal microscopy
To diminish the autofluorescence in the formaldehyde-fixed hippocampi, the paraffin sections were irradiated with light (Philips, Holland 40 W, 301 * CO, 230 V, spoltineR63) for 48 h. 20 Hereafter, the paraffin sections were deparaffinized in xylene and rehydrated in graded ethanols. The sections were washed in TBS (pH 7.6) and heated in TBS in a pressure cooker for 20 min. After cooling down, the sections were washed twice in TBS and incubated for 48 h at 41C with (i) a mouse monoclonal antibody recognizing abnormal tau protein (MC-1 21 ), in combination with the rabbit polyclonal anti-GFAP þ 1 (bleeding 010498; 1 : 100 MC-1/1 : 1000 GFAP þ 1 ) in supermix (0.05 M Tris, 0.9% NaCl, 0.25% gelatin and 0.5% Triton X-100, pH 7.6) or (ii) a combination of MC-1 (1 : 100) and GFAP wt (1 : 5000, DAKO, Carpinteria, CA, USA). Subsequently, the sections were washed in TBS and incubated for 1 h with anti-mouse-Cy2 (Jackson ImmunoResearch Labs; 1 : 50)/anti-rabbitCy3 (Jackson ImmunoResearch Labs; 1 : 200)/TO-PRO-3 (Molecular Probes; 1 : 1000). Sections were embedded in Mowiol (0.1 M Tris-HCl pH 8.5, 25% glycerol, 10% w/v Mowiol 4-88). Images were acquired by confocal laser scanning microscopy (Zeiss 510).
In situ hybridization Neuron-specific enolase (NSE) immunostaining was combined with GFAP in situ hybridization on 6 mm paraffin sections of a 70-year-old female AD patient (NBB-83002). The sections were deparaffinized, rehydrated and rinsed in RNAse-free TBS. Monoclonal anti-NSE (1 : 100 Novo-Castra in supermix) was applied to the sections for an overnight incubation at 41C. Subsequently, the sections were rinsed in TBS followed by an incubation with biotin-labeled horseanti-mouse (Vector, Burlingame, CA, USA; 1 : 400 in supermix) at room temperature for 1 h. After another rinse in TBS, the sections were incubated with avidin biotin complex (ABC, Vector Burlingame, CA, USA; 1 : 1000 in supermix) at room temperature for 45 min. The sections were rinsed with TBS and stained with diaminobenzidine in 0.05 M Tris buffer (pH 7.6). After a 2 Â 2 min wash in PBS, the sections were deproteinized and processed for in situ hybridization as described before. 4 A 40-mer oligonucleotide probe (see Figure 1a) complementary to nt 2328-2367 of GFAP mRNA (5 0 -CTTAATTCCCACAATCCAGAGGC-CAGTGCAACTGGTCAC-3 0 ) was labeled using terminal transferase and 35 S-dATP. Control hybridizations were performed with a sense probe 5 0 -GTGAC-CAGTTGCACTTGGCCTCTGGATTG TGGGAATTA-AG-3 0 .
Nonradioactive in situ hybridization Nonradioactive in situ hybridization was performed on formalin-fixed, paraffin-embedded human postmortem hippocampus of a 66-year-old male AD patient (NBB-88073). Digoxigenin-labeled (DIG) GFAP sense and antisense cRNA was generated by in vitro transcription using T3 or T7 RNA polymerase, respectively. The RNA was transcribed from human GFAP cDNA nt 1121-1295 (see Figure 1a) . The tissue sections (6 mm) were deparaffinized, rehydrated and treated with proteinase K (10 mg/ml in 10 mM TrisHCl, pH 7.5, 2 mM CaCl 2 ) at 371C for 30 min. The sections were postfixed in 4% buffered formalin in PBS for 5 min, followed by an incubation in ammonium chloride (1% in PBS) for 15 min. After rinsing twice with PBS, the sections were incubated in 0.1% Triton X-100 in PBS for 20 min. The sections were hybridized with 200-400 ng/ml DIG-RNA in 200 ml hybridization mix (50% formamid, 2 Â SSC, 10% dextran sulfate, 1 Â Denhardt's, 5 mM EDTA, 10 mM phosphate buffer (pH 8.0), 0.5 mg/ml tRNA overnight at 551C). After hybridization, the sections were washed in 2 Â SSC at room temperature for 30 min, 2 Â SSC at 651C for 60 min and 0.1 SSC at 651C for 60 min. Sections were transferred to buffer 1 (100 mM Tris-HCl, 150 mM NaCl, pH 7.4). Before immunostaining, the sections were blocked with 5% FCS, 0.3% triton in TBS at room temperature for 1 h, followed by an overnight incubation with anti-DIG antiserum conjugated to alkaline phosphatase (1 : 5000 in buffer 1, 1% FCS, no triton) at room temperature. The sections were washed 3 Â 5 min with buffer 1, equilibrated in buffer 2 (100 mM Tris-HCl, 50 mM MgCl 2 , 100 mM NaCl, pH 9.5) and the signal was visualized with NBT/BCIP overnight at RT. Staining was stopped by rinsing in TE pH 8 and slides were shortly dehydrated in graded alcohols.
Detection of mutation by expression cloning and immunoscreening RNA was isolated from freshly frozen pieces of autopsy brain tissue with Trizol (Gibco-BRL) according to the manufacturer's protocol. Total RNA (2 mg) was primed with random hexamers and reverse transcribed with Expand reverse transcriptase at 421C (Roche Molecular Biochemicals, Mannheim, Germany). A fragment of GFAP was amplified (nt 864-1290, Figure 1a and b) using high-fidelity taq polymerase (Roche). Primers used were: 5 0 -TTGCGGGATCCCCAGTTGCAGTCCTTGACCT-3 0 (nt 864-883) and 5 0 -TCGAAGCTTGTGCTCCTGCTTG-GACT-3 0 (nt 1290-1271). For exact position of primers see Figure 1a and b. Timing and temperatures were: 551C for 30 s, 721C for 30 s and 921C for 30 s for 40 cycles. The amplified product was isolated from the agarose gel and cloned in frame in the prokaryotic expression vector PQE31 (Qiagen) or pBKS-(Stratagene). After transformation, the protein production was induced by IPTG. Bacterial clones were copied to nitrocellulose filters. The filters were baked and stained for the GFAP þ 1 protein. Several clones that were producing GFAP þ 1 immunoreactive protein were identified and their inserts were sequenced with the Sequenase version 2 kit (USB, Cleveland, OH, USA).
Results
Designing the antibody against frameshifted GFAP
The sequence of the human GFAP gene can be found in GenBank as part of the 'homo sapiens chromosome 17 working draft sequence segment' (accession number NT 010765, GFAP gene nt 189463-199332). We deduced the exon-exon boundaries by comparing the known exon-exon transitions in the mouse GFAP mRNA (GenBank accession number X02801) with the highly homologous (87%) human GFAP mRNA (GenBank accession number J04569). 12 The human GFAP mRNA is 3017 bp in length and consists of nine exons; exon 1 nt 1-464, exon 2 nt 465-525, exon 3 nt 526-621, exon 4 nt 622-783, exon 5 nt 784-909, exon 6 nt 910-1130, exon 7 nt 1131-1174, exon 8 1175-1260 and exon 9 1261-3017. The coding region starts at nt 4 and stops early in exon 9 at nt 1302 ( Figure 1a) .
The initial focus of our studies was to find out whether molecular misreading of the GFAP gene occurs. From our earlier studies, we know that shortrepetitive sequences, like GAGAG, are hotspots for molecular misreading. 4, 22 The mRNA sequence of GFAP includes 10 GAGAG-motifs and six of these are The sequence between the forward and reverse PCR primers was amplified and cloned into a prokaryotic expression vector for the immunoscreening approach. The GFAP þ 1 antibody was raised against the very C-terminus of the frame-shifted GFAP protein, that is, DRGDAGWRGH (bold amino acids). This peptide was chosen based on an anticipated dinucleotide deletion in the GAGAG motif at position 922-926, which would give rise to a mutant GFAP protein, that is, GFAP þ 1 , with an extended out-of-frame C-terminus.
within the coding region (Figure 1a) . Classical molecular misreading 4 would result in a dinucleotide deletion in one of these motifs or adjacent to such a sequence. Since only a dinucleotide deletion in the fifth motif would result in an extended frameshifted C-terminus (Figure 1b) , we decided to raise a rabbit polyclonal antibody against this putative frameshifted GFAP protein, that is, DRGDAGWRGH, as described before. 4 An extensive BLAST search was performed to exclude homology of the 10 amino-acid long Cterminal sequence DRGDAGWRGH to other proteins. Furthermore, this sequence was compared to all six reading frames of the nonredundant nucleotide database in GenBank to check for homology. Neither the protein BLAST nor the nucleotide BLAST revealed other proteins or genes, except for GFAP, that show homology to DRGDAGWRGH. We termed the partly frameshifted GFAP as GFAP þ 1 , in accordance with APP þ 1 and UBB þ 1 proteins reported earlier. 4 The GFAP þ 1 antibody does not crossreact with purified human GFAP wt protein (ICN Biomedicals; Western blot: results not shown).
Frameshifted GFAP protein is expressed in neurons in the hippocampus of patients with AD pathology To test whether molecular misreading of the GFAP gene can occur, we started by analyzing the expression of the frameshifted GFAP protein, GFAP þ 1 , in the human hippocampus. The group of subjects consisted of 20 nondemented controls (age 34-90 years, 13 male, seven female), 15 AD patients (age 40-92 years, six male, nine female) and five DS patients (age 58-67 years, one male, four female). Paraffin sections of hippocampi of these patients were immunostained for the presence of GFAP þ 1 and GFAP wt (Table 1) . Because GFAP is believed to be a cell-specific marker for astrocytes, we expected GFAP þ 1 protein expression to be confined to astrocytes. In nondemented controls, without AD neuropathology, no GFAP þ 1 immunoreactivity was observed (Figure 2a) . Surprisingly, the GFAP þ 1 immunopositive cells observed in elderly controls and AD patients were primarily neurons (Figure 2c and e, arrowheads), although some sporadic astrocytes were immunopositive as well. GFAP þ 1 immunoreactivity was observed in the hippocampus of 12 AD patients, and also in five DS patients (Table 1) , who suffer from age-dependent Alzheimer-type neurodegeneration. 23 Although GFAP þ 1 -expressing neurons were mainly restricted to AD and DS patients, a few isolated GFAP þ 1 immunopositive neurons were found in the entorhinal cortex and CA1 area of four out of 21 nondemented controls (Figure 2c , arrowhead). In the hippocampi of these nondemented controls, neuropathological changes, that is, plaques and tangles, were observed as well. Three of the GFAP þ 1 immunopositive controls were older than 70 years (Table 1) . Immunostaining with the polyclonal antibody of DAKO, directed against bovine GFAP wt , revealed the expected presence of GFAP in astrocytes in each case (Figure 2b, d and f, arrows) . Careful examination of the paraffin sections stained for GFAP wt confirmed that pyramidal neurons in the hippocampus indeed were GFAP immunopositive (Figure 2f, arrowheads) , but only in AD and DS patients and in some nondemented controls with initial neuropathology (Table 1 ). The GFAP þ 1 preimmune serum showed no staining at all (results not shown). The GFAP wt expressing neurons in the paraffin sections showed a discrete, but weak, immunopositive signal compared to the astrocytic staining.
To consolidate these data, we successively immunostained 50 mm thick vibratome sections of a 92-yearold female AD patient (NBB-96115). Both, astrocytes and pyramidal neurons in the hippocampus were clearly stained with the DAKO polyclonal GFAP wt antibody (Figure 3a and c) . In contrast, mainly neurons, including tangle-shaped neurons, express GFAP þ 1 (Figure 3b ). An occasional GFAP þ 1 immunopositive astrocyte is observed as well (Figure 3d 
GFAP mRNA is expressed in neurons
We validated the presence of neuronal GFAP protein by studying the expression of GFAP mRNA in neurons by two different in situ hybridization methods, with either a 35 S-labeled oligonucleotide or a digoxigenin-labeled riboprobe (see Figure 1a for probe positions). With the 35 S-labeled 50 mer GFAP oligonucleotide hybridizations, we observed GFAP expression in cells that were NSE immunopositive (Figure 5a and b, arrows) . In agreement with the increased expression of GFAP mRNA in activated, intense clusters of silver grains were also observed in NSE-negative cells (Figure 5a and b, arrowheads) . The hybridization with the sense probe showed no signal. The nonradioactive in situ hybridization showed conclusively that GFAP mRNA is expressed in tangles (Figure 5c, arrow) . Many GFAP-expressing astrocytes were observed as well (Figure 5d , e and f, arrowheads). Additionally, we observed that GFAP mRNA (Figure 5e ) and GFAP protein (Figure 5f ) coexist in neurons and glia in consecutive sections. The results of the in situ hybridization confirm the protein data, thereby corroborating the finding that GFAP is expressed in these neurons.
Neuronal, but not astroglial, GFAP þ 1 expression is associated with AD pathology To analyze whether GFAP þ 1 immunostaining is associated with AD and DS, and not merely the result of gliosis, GFAP and GFAP þ 1 stainings were performed on hippocampal sections of 12 patients suffering from pharmaco-resistant temporal lobe epilepsy (Table 2 ). This hippocampal tissue is obtained by tissue biopsies and is fixed in formalin for a short period (1 day), compared to the 1-month fixation of post-mortem AD and DS patients' hippocampi. Therefore, five hippocampi from nondemented control patients with a fixation time of 1 day were included as controls for this study. As an additional control, a hippocampus from AD patients with 1-day fixation time was stained for GFAP þ 1 expression. Pyramidal neurons in this hippocampus were positive for GFAP þ 1 , indicating that the short fixation time did not influence immunostaining of the tissue. The epilepsy patients are classified into two groups: patients with severe hippocampal sclerosis (HS) and without sclerosis (non-HS). Especially, patients with severe HS are known to display an increase in GFAP immunoreactivity. 24 In none of the epileptic patients staining was observed in a few astrocytes in three HS patients and one non-HS patient; only two or three GFAP þ 1 immunopositive astrocytes per section were found, which is comparable to the number of GFAP þ 1 immunopositive astrocytes in AD and control patients. Therefore, our data indicate that the occurrence of the GFAP þ 1 protein in neurons is associated with AD pathology. In fact, additional immunostainings on the temporal cortex showed that GFAP is also expressed in tangle-shaped neurons in the temporal cortex of patients with AD pathology (data not shown).
Subsequently, a confocal study on hippocampal sections of AD patients was performed with antibodies against GFAP þ 1 or GFAP wt and an antibody directed against abnormally phosphorylated tau, that is, MC-1. This double-labeling experiment showed that GFAP þ 1 is indeed coexpressed with abnormally phosphorylated tau (p-Tau; MC-1 antibody) in a number of tangle-shaped neurons in the hippocampus of patients with AD pathology (Figure 6a ). Some neurons also coexpressed GFAP wt and p-Tau ( Figure  6b ). In Figure 6b , clearly cells can be identified that not only express GFAP wt (arrowhead) or p-TAU (asterisk), but also cells that coexpress GFAP wt and p-Tau (arrows).
Coexpression with other frameshifted proteins Earlier, we have reported on the expression of two frameshifted proteins in AD neurons, that is, APP þ 1 and UBB þ 1 . 4 To characterize the neurons that do express GFAP þ 1 further, we stained three consecutive 6-mm-thick paraffin sections of a 70-year-old female AD patient (NBB-83002) for the expression of UBB þ 1 (Figure 7a and d) , GFAP þ 1 (Figure 7b and e) and APP þ 1 (Figure 7c and f) . We observed a clear colocalization of GFAP þ 1 , APP þ 1 and UBB þ 1 in several neurons in the hippocampus of this AD patient (Figure 7) , suggesting a common pathway resulting in the accumulation of frameshifted proteins.
Splice variants of GFAP
In order to find out whether molecular misreading underlies the expression of the GFAP þ 1 protein in neurons, we examined the occurrence of frameshifted transcripts expressed in the human brain. Total RNA was isolated from two nondemented controls (NBB-97159, NBB-98006), two AD patients (NBB-89057, NBB-96115) and two DS patients (NBB-89055, NBB-93028) (footnote * in Table 1 ). GFAP was amplified by polymerase chain reaction (PCR) using Taq polymerase with proofreading capacity to avoid introduction of mutations. We amplified only part of the mRNA, that is, nt 864-1290 (GenBank accession number J04569), which includes the predicted frameshift mutation in the fifth GAGAG motif (Figure 1b) . The resulting PCR product was cloned in a prokaryotic expression vector, protein expression was induced and GFAP þ 1 immunonegative and immunopositive colonies were sequenced. All six patients, AD, DS as well as the nondemented controls, revealed immunopositive clones, indicating transcripts with frameshift mutations. The immunonegative colonies were all either GFAP wt , or contained a PCR-product with a 135 nt in-frame deletion of GFAP wt (D nt 910-1044). The D 135 variant was found in the following patients, NBB 98057 (AD), 89052 (DS) and 93028 (DS). In contrast to dinucleotide deletions that we found earlier in APP and UBB mRNA, 4 we found two additional GFAP out-of-frame splice forms (Figure 8a The arrowheads indicate GFAP-expressing astrocytes. The sections were counterstained with hematoxylin. With DIGlabeled riboprobes, tangles (c, arrow) and astroycytes (d, arrow heads) were observed in the hippocampus of an AD patient (NBB: 88073). The GFAP mRNA (e) colocalizes with GFAP wt immunoreactivity (f). A tangle-shaped neuron (arrow) and astrocytes (arrowheads) express GFAP mRNA (e) as well as protein (f). The inset shows a higher magnification of the tangle-shaped neuron. NSEIR¼neuron-specific enolase immunoreactivity, bar¼50 mm. exon 6 splice form was found in NBB 98006 (CON) and NBB 96115 (AD) and the D 164 form was found in NBB 89052 (DS) and NBB 93028 (DS). The D 135 form results in the translation of a shorter GFAP wt protein, which lacks part of coil 2B. The two out-of-frame splice forms, that is, D exon 6 and D164, are translated in GFAP proteins, which lack part of coil 2B and the entire tail region. The frameshifted C-terminus of these proteins contain the complete epitope that is recognized by the GFAP þ 1 antibody (Figures 8b  and 1b) .
Discussion
Our study provides clear evidence that GFAP is not exclusively expressed by glial cells, as has been the consensus for many years. Remarkably, we also observed the expression of GFAP mRNA and protein in hippocampal neurons in AD and DS patients and aged controls with early AD type of pathology. This neuronal GFAP, GFAP
, is an out-of-frame variant of GFAP wt and is the product of two novel splice forms of GFAP mRNA. In total, three novel splice forms were found, which are expressed in nondemented controls as well as AD and DS patients. The expression of the GFAP þ 1 protein in the hippocampus, however, is confined to a population of pyramidal neurons in areas with AD pathology, in AD and DS patients and in elderly nondemented controls.
GFAP is a classical marker for glia cells, including astrocytes. An extensive literature search revealed two papers describing possible GFAP expression in neurons. (i) In tuberous sclerosis patients, the typical giant cells in the brain show neuronal as well as glial cell-like features. These giant neuronal-like cells express GFAP. 25 (ii) In AD patients, it has been described that occasionally hippocampal neurofibrillary tangles were GFAP immunopositive, using a monoclonal GFAP antibody. 7 It has been discussed before that GFAP-immunopositive tangles in AD brains are actually GFAP-immunopositive fine processes of astrocytes that penetrate the bundles of paired helical filaments in ghost tangles. 26, 27 Our data, however, provide strong evidence that GFAP is expressed in neurons that are no ghost tangles, since the GFAP wt and GFAP þ 1 antibodies stain neurons in which a nucleus is visible. Furthermore, the presence of GFAP mRNA in neurons (Figure 5a , c and e) proves that the GFAP immunostaining observed in the neurons is indeed the result of GFAP expression. However, we cannot exclude the fact that GFAP wt is also expressed by these cells, since the probe used for in situ hybridization recognizes the novel GFAP splice forms and the full-length GFAP wt mRNA. Furthermore, the GFAP wt antibody of DAKO will stain GFAP wt protein as well as GFAP þ 1 protein. GFAP immunostaining is routinely performed on paraffin-or formalin-fixed frozen sections of the human brain. Our experience is that neuronal GFAP staining in paraffin sections is much weaker compared to the staining in the thicker vibratome sections, which might explain why other researchers have never appreciated the neuronal staining as a genuine staining. As mentioned before, GFAP-immunopositive neurons have been reported by others, but this staining has been explained as astrocytic processes engulfing ghost tangles. 27 By staining 50 mm thick vibratome sections, the intraneuronal expression of GFAP could be observed, indicating that these cells are not ghost tangles.
By expression cloning, we observed that the presence of the GFAP þ 1 protein was caused by the expression of novel GFAP out-of-frame splice forms. The neuronal GFAP þ 1 protein is either the translational product of the D 164 mRNA or of the D exon 6 GFAP mRNA. In addition to the out-of frame splice forms, we also observed a novel in-frame GFAP splice form, that is, D 135. Alternative splicing of GFAP has been reported by others, [28] [29] [30] [31] but the splice forms of the present study have not been described before. Since we were specifically aiming at studying the occurrence of molecular misreading around the GAGAG motif in exon 6, we amplified by PCR the part of the mRNA that starts in exon 5 and includes the coding region of the final C-terminus of the GFAP wt protein. Further studies are needed to investigate the full-length cDNAs of the splice forms described in this study. Our approach, though, clearly 
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showed that three novel splice forms are expressed in the human brain and two of these splice forms explain the presence of the GFAP þ 1 protein in hippocampal neurons.
Eukaryotic pre-mRNA splicing is regulated by consensus sequences at the intron boundaries and branch site. 32 According to the GT-AG splicing rule, the splice acceptor site consensus sequence is GTAAGT and the splice donor site consensus sequence is Py 12 NCAG. The GFAP D 135 form is an inframe alternative splice form, since the 5'splice site is the splice donor of intron 5 and the 3'splice site is a splice site consensus sequence (Py 12 NCAG) in exon 6, that is, ggCCCgCCaCTTGCAG. The GFAP D exon 6 form is an out-of-frame alternative splice form and the GFAP D 164 form is an out-of-frame cryptic splice form, since both the splice acceptor (5 0 -CAG-GAGGCGCT------) as well as the splice donor (--------GATCCACCAT-3 0 ) do not resemble splice sites' consensus sequences.
GFAP is the major component of the intermediate filaments in mature astrocytes, 33 and is important for providing mechanical strength to astrocytes. The precise function of GFAP, however, is still not well understood. For instance, GFAP knockout mice appear to be normal and show no obvious anatomical abnormalities in the CNS. 34 However, an additional lack in vimentin in GFAP-/-astrocytes results in problems with the formation of intermediate filaments. 35 The 50 kDa human GFAP protein is, like other intermediate filaments, composed of a head, rod and tail region. 13 The novel splice forms described in the present study all lack part of the coil 2B and the out-of-frame splice forms completely lack the tail. The rod region plays an important role in the formation of 10 nm filaments and the tail region has been implicated to be involved in the interaction of the GFAP with other proteins. 36 Therefore, the novel GFAP isoforms might affect the structure of the cell, since it might interfere with the neuronal intermediate filaments.
The main question is why hippocampal neurons in AD patients start expressing a glia-specific transcript? It has been reported before that multipotent astroglia can differentiate in either astrocytes or neurons. 37 The immature astrocytes are mainly GFAP immunopositive, but are capable of changing their expression pattern and start expressing neuron-specific proteins, like neuron-specific markers b-III tubulin, L1 and microtubule-associated protein 2. In addition, it has been shown that oligodendrocyte precursor cells can revert to multipotential neural stem cells, which can differentiate in neurons and astrocytes. 38 The hallmark of neuronal stem cells is their capacity to generate new cells that will differentiate in either glia or neurons. It has been shown by several laboratories that in AD patients the neurons at risk, including neurons containing intracellular tangles, express cell cycle-related proteins, such as P16 and CDK4, 39 cdc2/cyclin B1, 40 and nucleolin. 41 Recently, it was reported that hippocampal pyramidal neurons complete a full S-phase, demonstrating that DNA replication occurs in neurons before neuronal death. 42 Therefore, we propose that the data on the initiation of the cell cycle in combination with our data on the induction of GFAP in AD hippocampal neurons reflect a retro-differentiation of these neurons. It might be a defense mechanism of the neuron, to survive and eventually, if survival is successful, differentiate in neurons again.
In the neurons that express the GFAP þ 1 protein other þ 1 proteins, APP þ 1 and UBB þ 1 , were also found. This finding implicates that neurons that do accumulate these proteins might have a general failure in the degradation of aberrant proteins. This is likely to be caused by the presence of UBB þ 1 in these neurons, since UBB þ 1 is known to inhibit proteasomal degradation 43, 44 and eventually cause neuronal death. 45 Therefore, aberrant proteins, including GFAP þ 1 , might become apparent in neurons in the hippocampus, due to an initiation of GFAP gene expression in combination with a failure in the proteasomal degradation machinery, which can be initiated by molecular misreading of the UBB gene.
